<?xml version="1.0" encoding="UTF-8"?>
<p id="Par6">
 <list list-type="bullet">
  <list-item>
   <p id="Par7">The therapy, especially in the advanced stages, seems complicated, and we are waiting the outcome of several hundreds of clinical trials, often duplicated and non-coordinated. Major drugs are mostly non-viral-specific: hydroxychloroquine, lopinavir/ritonavir, remdesivir, convalescent plasma/monoclonal antibody, camostat, and ivermectin. New drug development is clearly the first priority.</p>
  </list-item>
  <list-item>
   <p id="Par8">The role of immunity is crucial both to overcame the acute phase and for establishing the vaccine.</p>
  </list-item>
  <list-item>
   <p id="Par9">Exit from the acute phase and establishing the new protocol for the post-acute phase is of utter priority.</p>
  </list-item>
 </list>
</p>
